London-based AstraZeneca studied the new use in a much-heralded 2008 study, showing Crestor reduced heart attack, stroke and other problems by 44 percent in patients with normal cholesterol and ...

The new Crestor label says that it may be prescribed for apparently healthy people if they are older -- men 50 and over and women 60 and over -- and have one risk factor such as smoking or high ...

As of yet, Crestor isn't approved as a preventative for cardiovascular disease. But AstraZeneca plans to ask the FDA by midyear for new indications for the drug, based on the outcomes results from ...

FDA panel recommends wider use for CrestorThey also reduce inflammation, which plays a key role in heart disease. The inflammation specifically linked to cardiovascular problems is characterized ...

Howard Hutchinson, AstraZeneca’s chief medical officer, said the approval is a significant milestone for the firm and “this new indication adds to the significant body of evidence physicians use to ...

National Health Insurance Administration (NHIA) data showed that more than 570,000 people are taking Crestor with about NT$2.3 billion (US$74.1 million) spent on the drug each year. Chih said the ...

The randomized trial's IVUS primary end point for rosuvastatin and atorvastatin in patients with established CAD was statistically nonsignificant, AstraZeneca announced today for investors.

AURORA enrolled 2,776 patients aged 50–80 years who had begun maintenance hemodialysis or hemofiltration at least 3 months earlier at one of 280 centers in 25 countries. Use of statins within ...